I would have to reread my posts to see if I ever was adamant on the subject, vs. just having an opinion that it was unlikely.
I honestly have no idea what level of evidence the FDA expects to see before allowing a drug into P3 trials. On the safety side, I would expect the data would be salvageable. Many drugs have gone into P3 with poor quality P2 data (ONTY's recent failure was based on a P2 subset analysis), so the stsat validuty is not a blocker.
I am adamant that the data would never serve as proof of effeciveness. Would not even bee supportative data for a future submission.